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Abstract
Background We hypothesized that acarbose would delay conversion from
impaired glucose tolerance (IGT) to type 2 diabetes by alleviating postprandial
hyperglycaemia. Our study’s main objective was to investigate the effect of
acarbose in IGT-persons on their 2-h plasma glucose level and beta-cell
function.
Subjects and Methods The study included a random sample of 45–70-
year-old residents of Hoorn, Netherlands, with mean fasting plasma glucose
<7.8 mmol/L and mean 2-h plasma glucose of 8.6–11.1 mmol/L (measured
by two successive oral glucose tolerance tests). After a qualification period,
participants were randomized to acarbose treatment or placebo. Insulin
secretion and insulin sensitivity were measured by hyperglycaemic clamp.
After a 3-year treatment, analyses were performed of both the intention-to-
treat and the per-protocol groups.
Results Of the 12 093 residents who received postal invitations, 118
participants were randomized. The mean difference of the post-load plasma
glucose after 3 years, was −1.16 mmol/L (95% CI: −2.03; −0.17). The
absolute risk reduction for diabetes was 6% (95% CI: −9; 21). No effect was
seen on insulin secretion and insulin sensitivity.
Conclusions In patients with IGT, treatment with acarbose was associated
with beneficial effects on 2-h plasma glucose levels but not with improvement
of beta-cell function. Copyright  2008 John Wiley & Sons, Ltd.
Keywords impaired glucose tolerance; randomized control trial; acarbose;
prevention type 2 diabetes; beta-cell function; insulin secretion
Introduction
Approximately 11% of all Caucasians aged 40 and older suffer from
impaired glucose tolerance (IGT) [1–3]. The World Health Organiza-
tion distinguishes this glucose intolerance category for its two-fold risk
of cardiovascular disease [4–9]. Moreover, approximately a third of per-
sons with IGT develop type 2 diabetes within 5–10 years [10–14].
The main patho-physiological abnormalities responsible for IGT include a
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compromised beta-cell response to hyperglycaemia with
a loss of the first-phase insulin secretion and reduced
insulin sensitivity both in muscle and liver.
In a previous large multi-centre intervention trial
in persons with IGT (STOP-NIDDM), acarbose, an
alpha-glucosidase inhibitor, delayed conversion to type
2 diabetes [15–20]. However, those results have
been disputed as questions arose about the study’s
methods, analyses, and interpretations. Not only do the
postprandial glucose levels decrease, but also the fasting
glucose levels [20–22]. It was therefore questioned
if acarbose also improved insulin secretion or insulin
sensitivity.
Our single-centre trial, started before the STOP-NIDDM
trial results were published, studied the effect of chronic
lowering of postprandial glucose excursions on beta-cell
function and insulin sensitivity. Our primary objectives
were to investigate the effects of acarbose on the
distribution of the 2-h plasma glucose level following an
intake of 75 g of glucose, the incidence of conversion
to type 2 diabetes, on insulin secretion induced by
hyperglycaemia, and on insulin sensitivity.
Materials and methods
In a randomized, double-blind, placebo-controlled,
parallel-group study, we compared acarbose with placebo
in patients with IGT. The 3-year intervention was pre-
ceded by three pre-randomization study phases: an initial
screening, a 6-week qualification period, and a wash-out
period. The ethical committee of the VU University Med-
ical Centre approved the protocol. All participants gave
written informed consent.
We defined the primary outcome measure as the
plasma glucose level 2 h after oral intake of 75-g glucose
after 3 years of treatment [(oral glucose tolerance test
(OGTT)]. Assuming that the mean 2-h post-load glucose
level in patients with IGT, when treated with placebo,
increases 0.25 mmol/L in 3 years, that the mean level in
patients treated with acarbose decreases 0.25 mmol/L
in 3 years [21,22], and that the standard deviation
of the levels is stable in both groups and remains
equal to the standard deviation in the comparable sub-
population of the Hoorn Study survey (0.67 mmol/L) [3],
we determined that we would need 47 participants in
each treatment group to demonstrate the resulting 0.5-
mmol/L difference as statistically significant with alpha
(two-sided) = 0.05 and beta = 0.05. Thus, we needed
complete data from 94 participants to provide sufficient
statistical power.
Using the population register of the town of Hoorn in
the Netherlands, we mailed invitations to take a blood
glucose test to 12 093 randomly selected 45–74-year-old
persons. Of those, 6651 (55%) visited the study centre.
We immediately excluded anyone who had: diseases or
conditions likely to prevent completion of the study,
known uncorrected endocrine disorders, documented
gastrointestinal diseases, cholesterol >10 mmol/L or
triglycerides >10 mmol/L, treatment with lipid lowering
medication (with the exception of statins), a myocardial
infarction within the previous 6 months, impaired liver
function (AST/ALT >50 units/L), or impaired kidney
function (creatinine >150 mmol/L).
Of the remaining participants, the 3147 with fasting
plasma glucose levels >5.5 mmol/L underwent an oral
glucose tolerance test. That test identified 554 participants
with 2-h plasma glucose levels >7.8 mmol/L; they
returned 2 weeks later for a second test. In the end,
171 participants met the inclusion criteria: a mean fasting
plasma glucose level <7.8 mmol/L, a mean 2-h plasma
glucose level of 8.6–11.1 mmol/L, an HbA1c level ≤7.0%
and aged 45–70 years. These 171 participants were
selected for the qualification period. The mean 2-h plasma
glucose level of 8.6–11.1 mmol/L as inclusion criterion
was chosen because of the higher incidence of conversion
of diabetes [14].
At the start of the study, the World Health Organization
(WHO) definition of 1985 classified type 2 diabetes as a
fasting plasma glucose value of ≥7.8 mmol/L and/or a
2-h plasma glucose value of ≥11.1 mmol/L [22] and IGT
as a fasting plasma glucose value of <7.8 mmol/L and/or
a 2-h plasma glucose value of ≥7.8 and <11.1. In 1999,
during the study, the WHO lowered the fasting plasma
glucose value criterion for type 2 diabetes to ≥7.0 and for
IGT a fasting glucose value <7.0 (the 2-h plasma glucose
value remained unchanged) [23].
As the qualification period began, participants started
with one tablet of acarbose per day in week 1 and two
tablets per day in week 2; they reached the maintenance
dose of 50 mg three times each day in week 3 and
continued that dose through week 6. We selected this
dose because previous studies had demonstrated that
it significantly lowered postprandial blood glucose with
fewer side effects than a dose of 300 mg/day [20–22].
Participants were instructed to take their tablets with the
first bite of a meal.
At the end of the qualification period, participants
were considered eligible for the wash-out period and
subsequent trial if they met the following criteria: having
complied with the study procedures, having taken more
than 80% of the prescribed medication during week
3–6 of the qualification period (as determined from
returned tablet blisters), and having reported no adverse
effects that could threaten future compliance. All eligible
participants received placebo tablets for the 4-week wash-
out period.
After the qualification and wash-out periods, study
numbers were randomly assigned to the placebo or
the acarbose group generated by a computer at Bayer’s
biometric unit. The numbers were assigned in ascending
order in the sequence of the subject’s entry into the
intervention study. The identity of the treatment groups
was concealed until the final statistical analysis.
The intervention period lasted 3 years and 1 month.
After an initial 2 weeks of up-titration, participants
received either the maintenance dose of three 50 mg
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tablets of acarbose per day or placebo. Placebo tablets
matched the acarbose tablets in size, shape, and colour.
Counts of tablets remaining at the end of each 3-month
treatment period were recorded in a drug inventory form
as an indication of compliance.
Measurements
At the start of the intervention, we measured participants’
height, weight, and body mass index [23]. Fasting plasma
glucose was measured every 3 months, and participants
took an oral glucose tolerance test twice at intervals of
18 months. Tablets were not taken on the morning of
these measurements.
Fasting and 2-h post-load plasma glucose levels
were measured with a hexokinase method (Boehringer,
Mannheim, Germany). Plasma-specific insulin (milliu-
nits/L) was measured by an immuno-radiometric assay
(Medgenix Diagnostics, Fleurus, Belgium), and intact
proinsulin (milliunits/L) by an immuno-radiometric assay
based on antibodies (Dako, Cambridgeshire, United King-
dom). Total cholesterol, HDL cholesterol, and triglyc-
erides were measured by enzymatic methods (Roche,
Mannheim, Germany).
At the start of the intervention, participants underwent
a hyperglycaemic clamp after at least 12 h of fasting.
Lying down, they were administered a priming infusion
of saline (0.9%) and glucose (20%). Blood was sampled
through a cannula inserted into a vein on the back of the
hand of the other arm. The hand was placed in a thermo-
regulated box at 45 ◦C to arterialize the venous blood.
After infusion of a bolus of glucose (150 mg/kg), blood
glucose was measured with a glucose analyser (Yellow
Springs Instrument, Inc., Yellow Springs, OH, USA) at 2.5-
min intervals. Blood glucose was maintained for 170 min
at a hyperglycaemic level of 10 mmol/L. Insulin samples
were taken at 2.5-min intervals during the first 10 min
and at 5–10-min intervals for the remaining 160 min.
We estimated beta-cell function by assessing the first-
phase insulin secretion in the first 10 min of the clamp,
calculating (using the trapezoidal rule) the area under the
curve (AUCins0–10) of the insulin levels of the first 10 min
of the clamp. We also estimated insulin sensitivity. Under
stable conditions of constant hyperglycaemia, the amount
of glucose infused (mg/kg/min) equals the amount of
metabolized glucose (M). We calculated (again, using the
trapezoidal rule) the area under the curve of the glucose
infusion rate during the last 20 min of the clamp. The M
value divided by the average plasma insulin concentration
(I) during the same interval – the M/I ratio – provides a
measurement of tissue sensitivity to insulin (mg/kg/min
per milliunits/L). Finally, as a measurement of beta-cell
function adjusted for insulin sensitivity, we calculated the
ratio between the first insulin secretion phase and the
M/I.
Participation in the intervention was terminated for
any of the following reasons: refusal to cooperate,
emergence of inter-current illness, serious side effects,
or unacceptably high glucose levels.
We took final data measurements at the end of the
treatment period or when a participant converted to
diabetes. For participants who withdrew early, we tried
to determine the reason for termination and to carry out
as many scheduled follow-up measurements as possible,
giving highest priority to the primary efficacy measure.
In cases of loss to follow-up, we tried to determine the
reason for the loss and to obtain a final assessment of the
primary measure of efficacy.
Statistical analysis
We performed analyses of both the intention-to-treat and
the per-protocol populations. We removed participants
from the per-protocol analysis if a treatment code was
broken, laboratory results were unacceptable, or data
essential to statistical analyses were missing.
Using t tests, we compared fasting plasma glucose,
2-h post-load plasma glucose, HbA1c, and lipid levels
between the treatment groups. We performed primary
efficacy analyses for both the intention-to-treat and per-
protocol groups. In cases where a patient needed blood
glucose lowering treatment, we used the 2-h post-load
level measured prior to the start of the treatment. We
compared the mean differences between both fasting and
2-h post-load levels at the start of the intervention and
the last visit (t tests). We performed multiple regression
analysis with the last fasting and 2-h post-load levels as
the dependent variables, and the following independent
variables: an indicator variable for the treatment contrast
(0 = placebo; 1 = acarbose), the baseline fasting and 2-
h post-load plasma glucose levels, age, and sex. The
effects of acarbose treatment on levels of insulin secretion
and insulin sensitivity as measured by the clamp were
evaluated using linear regression analysis with acarbose
as the indicator variable adjusted for the baseline value,
age, and sex. Finally, we calculated the rate of conversion
to diabetes with relative risk reduction, attributable risk,
and absolute risk reduction.
Results
Of the 171 participants who entered the qualification
phase, 53 were ineligible to continue; therefore, 118
participants were randomized. From these participants,
25 persons (21.2%) had a fasting glucose value
>7.0 mmol/L, and had type 2 diabetes according to
the WHO99 criterion. By the end of the intervention,
52 participants had dropped out for various reasons,
leaving 66 participants with complete data sets for the
per-protocol analysis (Figure 1).
Table 1 summarizes demographic data of the par-
ticipants. The treatment groups showed no important
differences, with the exception of a statistically significant
difference in their levels of HbA1c [acarbose 5.9% (95%
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Subjects enrolled
Post-load glucose
>8.5 and <7.8 mmol/l
N = 171 
 
 
Completers
N = 30
Drop-outs
N = 22
Primary reason: 
Adverse event (N=8) 
Consent withdrawn (N=1) 
Death (N=3) 
Lack of efficacy (N=6) 
Lost to follow-up (N=1) 
Non-compliance (N=3) 
Drop-outs
N = 30
Primary reason: 
Adverse event (N=22) 
Consent withdrawn (N=2) 
Death (N=1) 
Lack of efficacy (N=2) 
Non-compliance (N=3) 
First screening
N = 6,651
OGTT (FPG> 5.5 mmol/l)
N = 6,651
Postal invitation
N = 12,093
Completers
N = 36
Placebo
N = 58
Acarbose
N = 60
Subjects randomized
N = 118
Figure 1. Overview of subject disposition
Table 1. Demographic characteristics of study participants at
screening
Variable
Placebo
n = 58
Acarbose
N = 60
Non-randomized
n = 53
Age (years) 56.5 ± 7.0 58.5 ± 7.9 56.7 ± 8
Sex (% male) 50.0 50.8 42.0
Body mass
index (kg/m2)
29.5 ± 3.8 28.4 ± 3.9 28.8 ± 4.1
Waist/hip ratio 0.89 ± 0.07 0.89 ± 0.09 0.89 ± 0.09
Fasting
glucose
(mmol/L)
6.5 ± 0.6 6.6 ± 0.5 6.5 ± 0.6
2-h post-load
glucose
(mmol/L)
9.5 ± 0.7 9.6 ± 0.7 9.7 ± 0.8
HbA1c (%) 5.6 ± 0.6 5.9 ± 0.5 5.7 ± 1.1
Current
smoker (%)
23.3 24.6 44.0
All data (except sex and smoking status) given as arithmetic mean ±
(standard deviation).
CI: 5.77; 6.03) versus placebo 5.6% (95% CI: 5.44; 5.76);
p < 0.05).
Tables 2 and 3 summarize the course of plasma glucose,
plasma insulin, and lipid levels by comparing mean values
at baseline and end of treatment. The 2-h post-load plasma
glucose showed a decrease in the acarbose group. Fasting
total triglycerides increased in participants on placebo
and decreased in participants on acarbose. Table 3 shows
the results of the regression analyses. In the intention-
to-treat analysis but not in the per-protocol analysis,
acarbose showed a statistically significant effect on the
2-h post-load levels.
Table 3 also shows the results of the regression analysis
of the clamp-derived variables of insulin secretion and
insulin sensitivity at baseline and after 3 years. For
this analysis, 52 participants (27 placebo, 25 acarbose)
underwent a hyperglycaemic clamp twice. Five of
these participants had converted to type 2 diabetes.
No statistically significant effect of acarbose could be
determined.
The rate of conversion to diabetes according to the
former WHO criterion (WHO85) in the placebo group was
24.1% and in the acarbose group was 18.3%. The relative
risk was 0.76 (95% CI: 0.38; 1.53), the attributable risk:
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Table 2. Descriptive course of test results
Placebo group Acarbose group
2-h post-load plasma glucose (mmol/L)
Baseline
Mean value 9.51 ± 0.66 (58) 9.58 ± 0.74 (60)
Last visit (per-protocol)
Mean value 8.57 ± 2.31 (36) 8.13 ± 2.41 (30)
Mean difference acarbose vs
placebo
−0.49 (95% CI: −0.56; 1.56)
Last visit (intention-to-treat)
Mean value 9.28 ± 2.71 (58) 8.18 ± 2.33 (60)
Mean difference acarbose vs
placebo
−1.16 (95% CI: −2.03;
−0.17)∗
Fasting plasma glucose (mmol/L)
Baseline
Mean value 6.50 ± 0.61 (58) 6.59 ± 0.56 (60)
Last visit (per-protocol)
Mean value 6.38 ± 0.99 (36) 6.34 ± 0.77 (30)
Mean difference acarbose vs
placebo
−0.06 (95% CI: −0.46; 0.34)
Last visit (intention-to-treat)
Mean value 6.58 ± 1.05 (58) 6.39 ± 0.77 (60)
Mean difference acarbose vs
placebo
−0.16 (95% CI: −0.48; 0.15)
Fasting total triglycerides (mmol/L)
Baseline
Mean value 2.09 ± 1.03 (53) 2.34 ± 1.58 (49)
Last visit (per-protocol)
Mean value 2.25 ± 1.43 (36) 2.19 ± 1.38 (30)
Last visit (intention-to-treat)
Mean value 2.45 ± 1.52 (53) 2.12 ± 1.22 (49)
Mean difference acarbose vs
placebo
−0.57(95% CI: −1.08;
−0.06)∗
All data given as arithmetic mean ± standard deviation (n).
∗p < 0.05.
Table 3. Linear regression analysis with acarbose as independent
variable
Dependent Added variables Beta (95% CI)
Post-load plasma
glucose (mmol/L)
Baseline post-load
glucose, age, sex
−1.18 (−2.11; −0.24)∗
Fasting plasma
glucose (mmol/L)
Baseline fasting
glucose, age, sex
−0.16 (−0.46; 0.15)
First insulin
secretion phase
Baseline first
insulin secretion,
age, sex
−5.07 (−11.96; 1.81)
Insulin sensitivitya Baseline insulin
sensitivity, age,
sex
1.34 (−2.28; 4.96)
Disposition index Baseline
disposition index,
age, sex
−7.28 (−80.56; 66.0)
aInsulin sensitivity, M/I value (M, amount of metabolized glucose/I,
average plasma insulin concentration).
∗p < 0.05.
−0.14 (95% CI: −0.46; 0.21), and the absolute risk
reduction 6% (95% CI: −9; 21).
The number of dropouts due to adverse events was
much higher with acarbose than with placebo (36.7%
versus 13.8%). Acarbose had a significantly higher rate of
side effects, mostly affecting the gastrointestinal system:
abdominal pain (13.1% versus 3.3%), diarrhea (19.7%
versus 1.7%), and flatulence (44.3% versus 3.3%). None
of the documented gastrointestinal adverse events was
regarded as serious. One participant in the acarbose group
died from colon carcinoma approximately 8 months after
the last treatment, but the death was not considered
related to this treatment.
Discussion
In this study, we evaluated the effects of a 3-year
treatment with acarbose in patients with IGT. The results
partially support our initial hypothesis. In both the per-
protocol and intention-to-treat analyses, acarbose lowered
the mean 2-h post-load plasma glucose; in the intention-
to-treat analysis the difference between acarbose and
placebo was statistically significant. We also observed
a statistically significant and clinically relevant decrease
in total triglycerides in the acarbose group. We found
no differences with regard to fasting glucose, HbA1c, or
conversion to diabetes nor did we observe any beneficial
effects of acarbose treatment on insulin secretion or
insulin sensitivity. The frequency and pattern of observed
adverse events did not deviate from the already known
safety profile of acarbose, which is associated with
gastrointestinal complaints. These results support those
of the STOP-NIDDM trial [18–20].
Despite screening a large population (12 093), we
identified only 118 eligible participants for the trial,
due to a high dropout rate. The main reason for this
premature dropout was gastrointestinal side effects. This
phenomenon limits the use of acarbose. Because of the
rate of premature dropouts (higher than in other acarbose
studies), we had data for only 66 participants for the
per-protocol analysis. This did not meet the requirement
of 47 participants in each treatment group necessary
for sufficient statistical power. We believe that this lack
of power is the main reason that our results were not
statistically significant in this analysis. Another limitation
of this study is that we could not calculate a power-
analysis on insulin secretion or insulin sensitivity, because
of a lack of information on a meaningful difference
in both measures and unknown standard deviations of
these measures in this population. However, if a decrease
of HbA1c and 2-h post-load glucose values would be
explained by insulin secretion or insulin sensitivity, a
statistically significant change should have occurred.
Finally, there was a small but significant HbA1c difference
between the acarbose and control group at baseline,
although there was no significant difference between the
post-load glucose levels.
Several other studies have looked at preventing or
delaying conversion of IGT to type 2 diabetes. All of
these studies had to screen large populations to find
sufficient numbers of eligible participants [15–20]. In
addition to the difficulty of finding participants, it is also
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very difficult to motivate patients with IGT to comply
with treatment protocols, especially when they are not
yet suffering hyperglycaemia-related complaints. These
are but two limitations of this kind of prevention study.
The STOP-NIDDM and a Chinese multi-centre study
are the other trials that analysed acarbose as a
diabetes prevention treatment. In contrast with our
study, the STOP-NIDDM trial showed a delay in the
conversion to diabetes [18–20]. In that study, the
maintenance dose of acarbose was twice the dose
in our study; this factor, among others, may explain
the inconsistent results. However, a systematic review
of alpha-glucosidase inhibitors concluded that dosages
higher than 150 mg/day had no better effect on glycaemic
control [23]. Moreover, the STOP-NIDDM trial results
have been questioned because the study used a modified
intention-to-treat analysis and there was a considerable
difference in participants who already had diabetes at
baseline. The Chinese study found no effect of acarbose on
the prevention of the development of type 2 diabetes [24].
No other study has presented data on the effects
of acarbose on insulin sensitivity and insulin secretion
with clamp-derived measures. We hypothesized that
acarbose would have a positive effect on insulin secretion
and thereby on beta-cell function by delaying the
gastrointestinal absorption of glucose and ameliorating
postprandial hyperglycaemia. However, we found no
such effect. This is in concordance with an acarbose
intervention study with patients with early diabetes [25].
In summary, our study showed that acarbose lowers 2-h
post-load plasma glucose, but failed to show that it delays
conversion to type 2 diabetes. We observed no effect of
acarbose on insulin secretion or insulin sensitivity.
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